Science and Therapeutic Area
We aim to develop first-in-class and best-in-class macromolecular drugs through original innovation.
We have established a globally integrated R&D process with four R&D centers worldwide. We have built up whole-industry-chain technology platforms and mechanism of innovation for macromolecular drugs covering from early discovery to industrialization.
US Innovation Center
San Francisco and Maryland lnnovation Centers focus on mechanistic studies of known and innovative targets, drug discovery, and precise screening of drug molecules in the field of oncology and autoimmune diseases. The Maryland Center is also responsible for overseas drug registration and clinical development.US laboratories closely follow the latest trends in biotechnological innovation and drug research and development.
China Innovation Center
Shanghai and Suzhou innovation centers are capable of conducting innovative drug discovery and development, including drug target discovery, candidate molecular screening and optimization, functional validation and process development, pilot production and technology transfer, drug registration and clinical development.China Innovation Center has excellent "full-process" R&D capability, and can rapidly develop various types of drugs based on our own innovation platforms.
We have established an integrated technology system that covers the entire lifecycle of Protein drugs from early R&D all the way to industrialization.
Integrated technology system covering the entire lifecycleof Protein drugs from early R&D to industrialization
Automated High-efficiency Screening Platform for Antibody Selection and Functional Assays
Human Transmembrane Receptor Protein Array and High-throughput Screening Platform
High-yielding Stable Expression Cell Lines Screening and Establishment Platform
Antibody Quality Research, Control and Assurance Platform
Antibody Humanization and Construction Platform
CHO Cell Fermentation Process Development Platform
Antibody Purification Process Development and Formulation Optimization Platform
Antibody-Drug Conjugates Research and Development Platform
siRNA Drugs Research and Development Platform
Note:Company′s core technology platform
Our capacity for original innovation enables us to achieve new target discoveries and validation during the early stages of drug development, which means a higher level of drug research, a greater chance of drug discovery and success, and a wider range of diseases. As we continue to explore and validate more innovative targets, more and more drug candidates will enter our R&D pipeline, thus providing continuous innovation for our sustainable development.